Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)

Unity Health Toronto

$100,000.00

Neuropilin-1 and transforming growth factor-beta interactions in immune regulation and tumour immunology

EF 2008-09

Résumé
Neuropilin-1 (Nrp1) is a multifunctional protein that plays an important role in many processes such as the formation of new blood vessels (angiogenesis) and the development of the nervous system. However, new studies reveal that it is capable of many other activities. Recently, we found that Nrp1 is a receptor for transforming growth factor-beta (TGF-beta). TGF-beta is a cytokine (soluble mediator that regulates immune functions) that plays a key role in immunity, angiogenesis and wound healing. However, it can also exert negative effects in several diseases resulting, for example, in organ failure (lungs, kidneys, heart), and the promotion of cancer progression and metastasis. We have shown that the interactions between Nrp1 and TGF-beta contribute to the proper regulation of the immune system, and identified some molecular mechanisms that may explain these effects. Furthermore, we found that breast cancer cells, which express Nrp1, capture TGF-beta and respond to this cytokine, and we believe that this increases their malignant potential. Therefore, we propose experiments to further study the mechanisms of action of Nrp1, and its role in immune regulation and cancer. Significance. Nrp1 is a multifunctional protein that interacts with several growth factors and/or their receptors. We propose to study novel interactions with TGF-beta that we hypothesize play important roles in immune regulation and tumour biology. These studies could lead to new therapies for cancer.
Programme
Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
183460
Name
Prud'Homme Gerald J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Immunology & Transplantation
Projecttitle
Neuropilin-1 and transforming growth factor-beta interactions in immune regulation and tumour immunology
Programtype2
Operating Grants
Orgnameinp2
Unity Health Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
Keyworddelim
Angiogenesis; Breast Cancer; Cancer Therapy; Neuropilin; Regulatory T Cells; Transforming Growth Factor Beta
Abstract
Neuropilin-1 (Nrp1) is a multifunctional protein that plays an important role in many processes such as the formation of new blood vessels (angiogenesis) and the development of the nervous system. However, new studies reveal that it is capable of many other activities. Recently, we found that Nrp1 is a receptor for transforming growth factor-beta (TGF-beta). TGF-beta is a cytokine (soluble mediator that regulates immune functions) that plays a key role in immunity, angiogenesis and wound healing. However, it can also exert negative effects in several diseases resulting, for example, in organ failure (lungs, kidneys, heart), and the promotion of cancer progression and metastasis. We have shown that the interactions between Nrp1 and TGF-beta contribute to the proper regulation of the immune system, and identified some molecular mechanisms that may explain these effects. Furthermore, we found that breast cancer cells, which express Nrp1, capture TGF-beta and respond to this cytokine, and we believe that this increases their malignant potential. Therefore, we propose experiments to further study the mechanisms of action of Nrp1, and its role in immune regulation and cancer. Significance. Nrp1 is a multifunctional protein that interacts with several growth factors and/or their receptors. We propose to study novel interactions with TGF-beta that we hypothesize play important roles in immune regulation and tumour biology. These studies could lead to new therapies for cancer.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Prud'Homme, Gerald J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~